Global Azelamide MEA Market Strategic Research Report

Scope of the Report

The global Azelamide MEA market size is predicted to grow from US$ 21.54 million in 2025 to US$ 33.71 million in 2032; it is expected to grow at a CAGR of 6.6% from 2026 to 2032.

In 2025, global sales volume of Azelamide MEA is estimated at approximately 143 tons, with the mainstream ex-works price at around USD 154/kg. Gross margin of major manufacturers is approximately 45%–65%.

Azelamide MEA, CAS No. 242132-61-2, is an azelaic acid derivative cosmetic active ingredient, in which MEA refers to the monoethanolamine structure. Compared with traditional azelaic acid, Azelamide MEA offers better water solubility, formulation mildness, and ease of use, making it more suitable for functional skincare and personal care formulations. It is not a conventional acid exfoliating ingredient, but is positioned more as a mild active ingredient for oil control, acne care, brightening, and skin conditioning.

The product is usually supplied in both powder and liquid forms. The powder form is mostly used as a high-purity cosmetic active ingredient, while the liquid form is generally a pre-dissolved or compound ingredient designed for easier formulation addition. It can be used in serum, lotion, cream, gel, scalp treatment, and localized care product. Its core value lies in retaining the advantages of the azelaic acid system in sebum regulation, acne-prone skin care, complexion improvement, and soothing care, while improving formulation compatibility through amidation and the MEA structure, thereby reducing the limitations of traditional azelaic acid in solubility, irritation, and formulation stability.

From a market positioning perspective, Azelamide MEA is a niche but fast-growing high-value cosmetic active ingredient, mainly serving segmented applications such as facial care, scalp care, and body care. As functional skincare continues to shift from single, strongly irritating acid ingredients toward milder, compound, and long-term-use solutions, Azelamide MEA is expected to gain further application potential in brand formulations.

Global key Azelamide MEA players cover Vevy Europe S.p.A., Beri Pharma, UCUS Biotech, Suzhou Health Chemicals, Suzhou Sunland Pharmatech, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Azelamide MEA market?

What factors are driving Azelamide MEA market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Azelamide MEA market opportunities vary by end market size?

How does Azelamide MEA break out by Type, by Application?

This report presents a comprehensive overview of the global Azelamide MEA market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• High Purity (≥98.5%)
• Regular Purity (95%–<98.5%)

Segment by Form

• Powder
• Liquid

Segment by Application

• Facial Care
• Scalp Care
• Body Care
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Azelamide MEA market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Facial Care, Scalp Care, Body Care evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact